Article in Antimicrobial agents and chemotherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
8 authors.
Eman G YoussefDivision of Infectious Diseases, The Lundquist Institute for Biomedical Innovation at Harbor-University of California Los Anegeles (UCLA) Medical Center, Torrance, California, USA.ORCID 0000-0002-3167-1347
Teclegiorgis GebremariamDivision of Infectious Diseases, The Lundquist Institute for Biomedical Innovation at Harbor-University of California Los Anegeles (UCLA) Medical Center, Torrance, California, USA.ORCID 0009-0005-6620-6401
Yiyou GuDivision of Infectious Diseases, The Lundquist Institute for Biomedical Innovation at Harbor-University of California Los Anegeles (UCLA) Medical Center, Torrance, California, USA.ORCID 0000-0002-8295-7222
Hoja PattersonUniversity of Texas Health Science Center at San Antonio, San Antonio, Texas, USA.
Sondus AlkhazrajiDivision of Infectious Diseases, The Lundquist Institute for Biomedical Innovation at Harbor-University of California Los Anegeles (UCLA) Medical Center, Torrance, California, USA.
Tasneem ElsayedDivision of Infectious Diseases, The Lundquist Institute for Biomedical Innovation at Harbor-University of California Los Anegeles (UCLA) Medical Center, Torrance, California, USA.
Nathan P WiederholdUniversity of Texas Health Science Center at San Antonio, San Antonio, Texas, USA.ORCID 0000-0002-2225-5122
Ashraf S IbrahimDivision of Infectious Diseases, The Lundquist Institute for Biomedical Innovation at Harbor-University of California Los Anegeles (UCLA) Medical Center, Torrance, California, USA.ORCID 0000-0003-3787-8530
Funding
Novel Toxins and Receptors in Mucormycosis Pathogenesis and TreatmentR01AI063503 · NIAID · LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER · PI IBRAHIM, ASHRAF S. · 2006 to 2025
$7.3M
Project 3P01AI186818 · NIAID · LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER · PI DIMITRIOS P KONTOYIANNIS · 2025 to 2026
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Efficacy assessments of EL219, a next-generation polyene antifungal, in immunosuppressed mice infected with drug-sensitive and drug-resistant · full record | OpenQuestion